On November 25, 2019, the U.S. Food and Drug Administration sent a warning letter to Chara Biologics, Inc. The warning letter outlines a review conducted by the Office of Compliance and Biologics Quality in the Center for Biologics Evaluation and Research stating that the firm markets the product CharaCoreā„¢ as containing "umbilical, cord tissue, and amniotic membrane" that is "suitable for all forms of injections, to assist the body's ability to repair and regenerate." The letter further states that the product appears to be a human cell, tissue, or cellular or tissue-based product that would be subject . . .
Content Restricted

This article is reserved for members with an active Standard Membership. Please purchase a Standard Membership to view this resource.

Purchase Standard Account

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!


Support Request

Need help now?

Call our toll-free phone number 877-350-6463